Mayo Clinic
Vatsvagiri vepaMayo Clinic Florida campus vakagamuchira mari yemubatanidzwa yemakore mashanu inosvika madhora miriyoni gumi nenhatu yekuyedza majekiseni akagadzirirwa kudzivirira kudzoka kwegomarara rezamu rakapetwa katatu. Kenza yemazamu katatu-negative imhando yegomarara rezamu rakaipisisa, uye parizvino hapana kurapwa kwakanangwa.
Varwere ve280 vachatora chikamu muyedzo yekiriniki iyi, iyo yakatanga mukutanga kwe2016.
The funding is a breakthrough award from the U.S. Department of Defense’s Breast Cancer Research Project and will be used to fund a nationwide phase II clinical trial to test the folate receptor alpha vaccine kudzivirira bundu iri rakaipisisa kuti risadzokorore mushure mekurapwa.
Chikamu chekutanga chekuyedza kiriniki chaisanganisira varwere makumi maviri nevaviri vaimbotungamirwa naKeith Knutson, PhD mune immunology, vakawana vaccine yakachengeteka. Iyo haina kukurudzira autoimmunity.
Mushonga uyu wakagadzirwa naDr. Knutson uye pakutanga wakaedzwa neveMayo Clinic Rochester campus vatsvakurudzi kuti vaongorore kuchengeteka uye kukwanisa kukurudzira immune system.
It takes advantage of the characteristics of triple negative kenza yebonde that require folic acid intake. Dr. Knutson said that because of this need, these tumors synthesize a large amount of folate receptor alpha, which is used to latch folic acid into the tumor’s microenvironment.
Pane humbowo hwekuti vamwe varwere vanogona kugadzika maitiro ekudzivirira muviri kune aya ma receptors. "Asi kenza yakanyanya kusimba kune iyi isina simba rekuzvidzivirira," Dr. Knutson akadaro.
The purpose of the vaccine is to promote the immune system to respond quickly to cancer cell receptors during the early stages of tumarara kudzokorora.
Iye akati, "Tinotenda kuti jekiseni rinopa mhinduro yakasimba uye isingaperi kune anenge apihwa, izvo zvinozovandudza kugona kwemuviri kuwana folic acid nekucheka bundu uye kuuraya bundu racho zvakananga kana zvisina kunanga."
